Core Viewpoint - The stock of Xinwei Medical-B (06609) has risen over 10%, currently trading at HKD 56.75, with a transaction volume of HKD 13.4465 million, driven by positive expectations regarding its upcoming interim results [1] Financial Performance - Xinwei Medical anticipates a net profit attributable to shareholders of no less than RMB 40 million for the first half of 2025, marking a turnaround from a loss to a profit [1] - The increase in revenue is primarily attributed to the sales growth of newly launched hemorrhagic stroke treatment devices and acute ischemic stroke treatment devices [1] Cost Management - Effective cost control measures have led to a decrease in overall expense ratios for the group [1] - Changes in the research and development phase of projects have resulted in reduced R&D expenditures [1] Financial Assets - There has been an increase in the fair value gains of financial assets measured at fair value through profit or loss [1]
心玮医疗-B绩前涨超10% 公司预计上半年扭亏为盈赚逾4000万元